CAT 2024 Slot 3 VARC: The Ethics of Gene Editing

The advent of CRISPR-Cas9 and related gene-editing technologies has compressed what was once a decades-long project of genetic modification into a matter of weeks, and in doing so it has forced ethicists, scientists and policymakers to confront questions that were, until recently, comfortably hypothetical. The technology's precision and affordability mean that altering the human germline — the DNA passed from parents to children — is no longer a remote possibility confined to speculative fiction but a practical option that a well-equipped laboratory could attempt today. This has split the scientific community into two broad camps, though the division is less a matter of expertise than of underlying values.

The first camp treats gene editing as a natural extension of medicine's long project of relieving suffering. On this view, if a heritable mutation causes a devastating disease, correcting it in an embryo is no different in kind from other interventions doctors already sanction, such as removing a cancerous growth or vaccinating a child. To withhold a cure because it operates at the level of the genome, proponents argue, is to privilege a sentimental notion of the 'natural' over the wellbeing of actual, particular children who would otherwise inherit the disease. They further note that many societies already permit forms of genetic selection, such as preimplantation screening to avoid transferring embryos with known chromosomal disorders, so germline editing is best understood as an incremental refinement of an accepted practice rather than a categorically new act.

The second camp resists this framing, and its objections cluster around three distinct concerns. The first is safety: because germline edits are transmitted to all descendants, an error — an 'off-target' cut in the wrong part of the genome, say — would not merely harm one patient but would propagate indefinitely through a lineage, with consequences no one alive today could fully anticipate or consent to. The second concern is about the boundary between therapy and enhancement. Curing an embryo of a fatal metabolic disorder is one thing; editing genes associated with height, cognition or temperament is another, and critics worry that the line between the two will prove far harder to hold in practice than in principle, since traits like intelligence are influenced by thousands of genes with effects that are probabilistic rather than deterministic, making any 'enhancement' as much a gamble as a guarantee. The third concern is distributive: if germline editing remains expensive, as novel medical technologies typically do for years after their introduction, it risks becoming another mechanism by which existing inequalities are not merely reproduced but literally written into the biology of future generations, converting an economic advantage into what looks like a natural one.

What makes the debate especially difficult to resolve is that it cannot be settled by better science alone. Improving the precision of the editing tools would answer the safety objection but leaves the therapy-enhancement boundary and the distributive worry entirely untouched. Some commentators have proposed international moratoria on heritable editing while regulatory frameworks catch up, a position that has considerable support among scientists themselves, including several of the technique's original developers. Yet a moratorium is, at best, a pause rather than an answer: it defers the argument without resolving the disagreement about what, if anything, would make germline editing legitimate. The most honest conclusion available at present may be that the technology has outpaced not our ability to use it, but our collective capacity to agree on the terms under which its use would be justified.